Sofinnova Ventures — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Board seatJames Healy· per SEC Form D
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLAVLilly Asia Ventures+2 more
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Board seatMaha Katabi· per SEC Form D
Co-investorsSamsara BioCapitalScion Life SciencesTCG CrossovervenBio PartnersVersant VenturesVivo Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.